Objective To explore the effect of complex trabeculectomy combined with Conbercept intravit‐real injection in the treatment of neovascular glaucoma .Methods 96 patients with NVG were randomly divided into control group and study g roup ,48 cases in each group .T he tw o groups w ere all given com‐plex trabeculectomy .T he study group w as treated w ith Conbercept intravitreal injection at 5‐7 d before surgery .T he iris neovascularization retrogression time ,intraocular pressure and vision level before and af‐ter operation ,levels of serum interleukin‐6 (IL‐6) ,vascular endothelial grow th factor (V EGF) ,transfor‐ming grow th factor beta 1 (T GF‐beta 1) and the incidence of complications w ere compared betw een the two groups .Results The retrogression time of iris neovascularization in the study group was significantly shorter than that of the control group ( P＜0 .01).A t 1 month and 3 months af ter operation ,the intraocu‐lar pressure of the two groups was significantly lower than that before operation (P＜0 .01) ,and the study g roup w as significantly low er than the control group ( P＜0 .01).T he visual acuity of the tw o g roups w as significantly higher than that before surgery ( P＜0 .01) ,and the study group w as significantly higher than the control group ( P＜0 .01).1 d af ter surgery ,the levels of serum interleukin‐6 ,vascular endothelial g row th factor ,transforming grow th factor beta 1 w ere significantly low er than those before surgery ( P＜0 .01).T he study group w as significantly low er than the control g roup ( P＜0 .01).T here w as no signifi‐cant difference in the incidence of complications betw een the tw o groups ( P＞0 .05).Conclusion Co mplex trabeculectomy com bined w ith Conbercept intravitreal injection can pro mo te the retrogression of iris neo‐vascularization ,reduce intraocular pressure and serum interleukin‐6 ,vascular endothelial grow th factor and transforming g row th factor beta 1 levels .It can also improve the level of vision ,w ith high security ,it is worth promoting .%目的 探讨复合式小梁切除术联合康柏西普玻璃体腔注射治疗新生血管性青光眼的临床疗效.方法 将96例新生血管性青光眼患者按照随机数字表法分为研究组与对照组各48例.两组均给予复合式小梁切除术,研究组在术前5d—7d给予康柏西普玻璃体腔注射治疗,比较两组虹膜新生血管消退时间,比较两组手术前后眼压及视力水平,血清白细胞介素‐6、血管内皮生长因子、转化生长因子β1水平,比较两组并发症发生率.结果 研究组虹膜新生血管消退时间显著短于对照组(P＜0 .01).术后1个月、3个月两组眼压较术前显著降低(P＜0 .01) ,研究组显著低于对照组(P＜0 .01) ,两组视力水平较术前显著升高(P＜0 .01) ,研究组显著高于对照组(P＜0 .01).术后1 d两组血清白细胞介素‐6 、血管内皮生长因子、转化生长因子β1水平均较术前显著降低(P＜0 .01) ,研究组显著低于对照组(P＜0 .01) .两组并发症发生率比较差异无统计学意义(P＞0 .05).结论 可促使虹膜新生血管消退,降低患者眼压及血清白细胞介素‐6 、血管内皮生长因子、转化生长因子β1水平,提高视力水平,安全性高,值得推广应用.
展开▼
